TY - CHAP A1 - José-Ángel Hernández A2 - Marcos González A3 - Jesús-María Hernández ED1 - Pablo Oppezzo Y1 - 2012-02-10 PY - 2012 T1 - Prognostic Factors in Chronic Lymphoid Leukemia and Identification of New Clinically Relevant Molecular Markers N2 - B-cell chronic lymphocytic leukemia (CLL) is considered a single disease with extremely variable course, and survival rates ranging from months to decades. It is clear that clinical heterogeneity reflects biologic diversity with at least two major subtypes in terms of cellular proliferation, clinical aggressiveness and prognosis. As CLL progresses, abnormal hematopoiesis results in pancitopenia and decreased immunoglobulin production, followed by nonspecific symptoms such as fatigue or malaise. A cure is usually not possible, and delayed treatment (until symptoms develop) is aimed at lengthening life and decreasing symptoms. Researchers are playing a lead role in investigating CLL's cause and the role of genetics in the pathogenesis of this disorder. Research programs are dedicated towards understanding the basic mechanisms underlying CLL with the hope of improving treatment options. BT - Chronic Lymphocytic Leukemia SP - Ch. 12 UR - https://doi.org/10.5772/27108 DO - 10.5772/27108 SN - PB - IntechOpen CY - Rijeka Y2 - 2021-06-18 ER -